title: [Treatment and control of cardiovascular risk in primary care in Spain. The PREVENCAT study].
abstract: OBJECTIVE
  The PREVENCAT study was designed to estimate the control of the main cardiovascular risk factors (CVRF) and their treatment in a sample of population having the diagnoses of hypertension (HT), type 2 diabetes mellitus (DM2) or hypercholesterolemia (HC) who was attended by primary care physicians in Spain.
  
  
  METHODS
  Cross-sectional study in patients with HT, DM2 and/or HC, who were consecutively recruited. We describe the treatments for HT, DM2 and HC and analyze and the association between several potential predictors and the control of these CVRF.
  
  
  RESULTS
  2,649 patients were included in the study. 95% of HT patients were under treatment, as were 84% of DM2 and 71.4% of HC patients; most common drugs were diuretics, sulphonylureas and statins, respectively. Monotherapy was more frequent than combined therapy for hypertension treatment. The frequency of HT and DM2 treatment was similar among the subgroups defined by the presence or absence of the other two diagnoses. However, HC treatment was more common in the presence of DM2 (p = 0.001). Age, previous cardiovascular disease (CVD), DM2, obesity and sedentarism were all predictors of poor blood pressure control despite drug treatment. Age, previous CVD, HT and sedentarism were predictors of poor HC control.
  
  
  CONCLUSIONS
  CVRF treatment was high although heterogeneous and not based on the best available evidence. DM2, previous CVD and obesity were associated with insufficient blood pressure control.
authors.affiliation: Instituto de Medicina y Dermatología, Hospital Clínic, IDIBAPS, Universidad de Barcelona, Barcelona, Spain. acoca@clinic.ub.es
authors.forename: Antonio
authors.initials: A
authors.lastname: Coca
authors.forename: Antonio
authors.initials: A
authors.lastname: Dalfó
authors.forename: Enric
authors.initials: E
authors.lastname: Esmatjes
authors.forename: José Luis
authors.initials: JL
authors.lastname: Llisterri
authors.forename: Jordi
authors.initials: J
authors.lastname: Ordóñez
authors.forename: Ramón
authors.initials: R
authors.lastname: Gomis
authors.forename: José Ramón
authors.initials: JR
authors.lastname: González-Juanatey
authors.forename: Armando
authors.initials: A
authors.lastname: Martín-Zurro
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D016009:Chi-Square Distribution; D016001:Confidence Intervals; D003627:Data Interpretation, Statistical; D003924:Diabetes Mellitus, Type 2 / Q000178:diet therapy / Q000188:drug therapy / Q000628:therapy*; D004232:Diuretics / Q000627:therapeutic use; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy*; D006973:Hypertension / Q000188:drug therapy* / Q000517:prevention & control; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D008019:Life Style; D008875:Middle Aged; D009765:Obesity / Q000150:complications; D011320:Primary Health Care; D012307:Risk Factors; D012737:Sex Factors; D013030:Spain; D013453:Sulfonylurea Compounds / Q000627:therapeutic use
chemical_list: D000924:Anticholesteremic Agents; D000959:Antihypertensive Agents; D004232:Diuretics; D007004:Hypoglycemic Agents; D013453:Sulfonylurea Compounds